DYNAMICS OF SERUM POTASSIUM CONCENTRATION DURING «TRIPLE-COMPONENT» AND «DUAL-COMPONENT» PHARMACOLOGICAL BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS ON THE MAINTENANCE HEMODIALYSIS

Abstract

THE AIM. To assess the safety and tolerability of management with dualcomponent ((lisinopril, and valsartan) and «triplecomponent» (lisinopril, valsartan, and spironolactone) pharmacological blockade of the reninangiotensinaldosterone system (RAAS) in patients with end stage renal disease treated with maintenance hemodialysis (MHD). PATIENTS AND METHODS. Patients was into the two groups: Group 1 (36 patients) receiving the «triplecomponent» scheme of RAAS blockade, and Group 2 (35 patients) received the «dualcomponent» therapy (lisinopril, valsartan). The duration of treatment period was 6 months. In both groups serum potassium concentration (SK) has been measured after 3 and 6 months of treatment. RESULTS. There were no clinically significant changes of SK in both groups during the entire period of treatment. Tolerability of both schemes was good. Nobody of patients experienced any side effects during the trial. CONCLUSIONS. Management with combined RAAS blockade (lyzinopril, valsartan, and spironolacton or lyzinopril, and valsartan) in MHD patients doesn’t induce hyperkalemia. It allows to continuing the investigation of cardioprotective efficacy of dual or triple blockade of RAAS in MHD patients.